Phase II LORELEI trial found that neoadjuvant letrozole plus taselisib for oestrogen receptor‐positive, HER2‐negative, early‐stage breast cancer increased the proportion of patients who achieved an objective response.357. Here, ERBB2 is linked to breast carcinoma.